06:09 EST Terns Pharmaceuticals (TERN) files automatic mixed securities shelf
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals price target raised to $56 from $36 at Barclays
- Promising Potential of TERN-701: A Strong Contender in the CML Treatment Landscape
- Terns Pharmaceuticals Unveils Promising Phase 1 Trial Data
- Terns Parmaceuticles trading resumes
- Terns jumps 40% after announcing Phase 1 data for TERN-701